These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 38156860)

  • 1. Clinicopathological Study of PD-1/PD-L1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with Emphasis on Large B-Cell Richter Transformation.
    Masoud R; Eladl AE; El-Ashwah S; Abbas A; Kandil W
    Asian Pac J Cancer Prev; 2023 Dec; 24(12):4243-4252. PubMed ID: 38156860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness.
    He R; Ding W; Viswanatha DS; Chen D; Shi M; Van Dyke D; Tian S; Dao LN; Parikh SA; Shanafelt TD; Call TG; Ansell SM; Leis JF; Mai M; Hanson CA; Rech KL
    Am J Surg Pathol; 2018 Jul; 42(7):843-854. PubMed ID: 29762141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma variant.
    El Hussein S; Medeiros LJ; Gruschkus SK; Wei P; Schlette E; Fang H; Jelloul FZ; Wang W; Fiskus W; Kanagal-Shamanna R; Loghavi S; Yang H; Li S; Xu J; Tang Z; Thakral B; Jain N; Wierda WG; Patel K; Bhalla KN; Khoury JD
    Virchows Arch; 2023 Jun; 482(6):1011-1019. PubMed ID: 36864257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
    Xie M; Huang X; Ye X; Qian W
    Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clonality relatedness and molecular characteristics of Richter transformation].
    Sha YQ; Jiang R; Miao Y; Qiu TL; Qin SC; Qiu JY; Mi HL; Wu W; Qiao C; Wu YJ; Xia Y; Wang L; Fan L; Xu W; Li JY; Zhu HY
    Zhonghua Xue Ye Xue Za Zhi; 2022 Oct; 43(10):841-847. PubMed ID: 36709198
    [No Abstract]   [Full Text] [Related]  

  • 6. Outcomes of Richter's transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): an analysis of the SEER database.
    Elnair R; Ellithi M; Kallam A; Shostrom V; Bociek RG
    Ann Hematol; 2021 Oct; 100(10):2513-2519. PubMed ID: 34279675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Richter syndrome: A rare complication of chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Wąsik-Szczepanek E; Szymczyk A; Szczepanek D; Wszoła-Kleinrok J; Chocholska S; Pluta A; Hus M
    Adv Clin Exp Med; 2018 Dec; 27(12):1683-1689. PubMed ID: 30156387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome.
    Wang Y; Sinha S; Wellik LE; Secreto CR; Rech KL; Call TG; Parikh SA; Kenderian SS; Muchtar E; Hayman SR; Koehler AB; Van Dyke DL; Leis JF; Slager SL; Dong H; Kay NE; He R; Ding W
    Blood Cancer J; 2021 May; 11(5):86. PubMed ID: 33972504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.
    Kiyasu J; Miyoshi H; Hirata A; Arakawa F; Ichikawa A; Niino D; Sugita Y; Yufu Y; Choi I; Abe Y; Uike N; Nagafuji K; Okamura T; Akashi K; Takayanagi R; Shiratsuchi M; Ohshima K
    Blood; 2015 Nov; 126(19):2193-201. PubMed ID: 26239088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment for acceleration and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma using histologic and immunohistochemical features: a case series.
    Moore ME; Aguilera NS; Obiorah I; Williams E; Courville E
    J Hematop; 2024 Sep; 17(3):139-147. PubMed ID: 39042242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microenvironment Remodeling and Subsequent Clinical Implications in Diffuse Large B-Cell Histologic Variant of Richter Syndrome.
    Augé H; Notarantonio AB; Morizot R; Quinquenel A; Fornecker LM; Hergalant S; Feugier P; Broséus J
    Front Immunol; 2020; 11():594841. PubMed ID: 33381116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computed tomography textural analysis for the differentiation of chronic lymphocytic leukemia and diffuse large B cell lymphoma of Richter syndrome.
    Reinert CP; Federmann B; Hofmann J; Bösmüller H; Wirths S; Fritz J; Horger M
    Eur Radiol; 2019 Dec; 29(12):6911-6921. PubMed ID: 31236702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Herpes simplex infection simulating Richter transformation: a series of four cases and review of the literature.
    Salem A; Loghavi S; Khoury JD; Agbay RL; Jorgensen JL; Medeiros LJ
    Histopathology; 2017 Apr; 70(5):821-831. PubMed ID: 27905140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histologic transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Agbay RL; Jain N; Loghavi S; Medeiros LJ; Khoury JD
    Am J Hematol; 2016 Oct; 91(10):1036-43. PubMed ID: 27414262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Large cell lymphoma transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. A flow cytometric analysis of seven cases.
    Kroft SH; Dawson DB; McKenna RW
    Am J Clin Pathol; 2001 Mar; 115(3):385-95. PubMed ID: 11242795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
    Xu-Monette ZY; Xiao M; Au Q; Padmanabhan R; Xu B; Hoe N; Rodríguez-Perales S; Torres-Ruiz R; Manyam GC; Visco C; Miao Y; Tan X; Zhang H; Tzankov A; Wang J; Dybkær K; Tam W; You H; Bhagat G; Hsi ED; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; van Krieken JH; Winter JN; Westin JR; Pham LV; Medeiros LJ; Rassidakis GZ; Li Y; Freeman GJ; Young KH
    Cancer Immunol Res; 2019 Apr; 7(4):644-657. PubMed ID: 30745366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.
    Ishikawa E; Kato S; Shimada K; Tanaka T; Suzuki Y; Satou A; Kohno K; Sakakibara A; Yamamura T; Nakamura M; Miyahara R; Goto H; Nakamura S; Hirooka Y
    Cancer Med; 2018 Dec; 7(12):6051-6063. PubMed ID: 30449068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma.
    Dong N; Rubio Lopes-Garcia L; Viñal D; Bachmeier C; Shah BD; Nishihori T; Khimani F; Davila ML; Lazaryan A; Pinilla-Ibarz J; Locke FL; Jain MD; Chavez JC
    Transplant Cell Ther; 2023 Jun; 29(6):349.e1-349.e8. PubMed ID: 36878427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TP53/PLCG2-mutated diffuse large B-cell lymphoma richter transformation (DLBCL-RT) of CLL with unusual CD2 and PD-1 expression.
    Symes E; Wang P; Lager AM; Bishop MR; Aqil B; Venkataraman G
    Leuk Lymphoma; 2022 Nov; 63(11):2735-2738. PubMed ID: 35719104
    [No Abstract]   [Full Text] [Related]  

  • 20. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
    Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
    Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.